
1. haematologica. 2017 jan;102(1):60-68. doi: 10.3324/haematol.2016.150227. epub
2016 sep 22.

erythroferrone contributes hepcidin repression mouse model malarial
anemia.

latour c(1), wlodarczyk mf(2), jung g(3), gineste a(1), blanchard n(2), ganz
t(3)(4), roth mp(1), coppin h(5), kautz l(5).

author information: 
(1)irsd, université de toulouse, inserm u1220, inra u1416, envt, ups, toulouse,
france.
(2)cptp, université de toulouse, cnrs u5282, inserm u1043, ups, toulouse, france.
(3)department pathology, david geffen school medicine, university of
california, los angeles, usa.
(4)department medicine, david geffen school medicine, university of
california, los angeles, usa.
(5)irsd, université de toulouse, inserm u1220, inra u1416, envt, ups, toulouse,
france leon.kautz@inserm.fr helene.coppin@inserm.fr.

malaria, major global health challenge worldwide, accompanied severe
anemia secondary hemolysis increased erythrophagocytosis. iron an
essential functional component erythrocyte hemoglobin availability 
controlled liver-derived hormone hepcidin. examined regulation of
hepcidin malarial infection mice using rodent parasite plasmodium
berghei k173. mice infected plasmodium berghei k173 develop severe anemia 
and die 18 22 days without cerebral malaria. early phase of
blood-stage infection (days 1 5), strong inflammatory signature was
associated increased production hepcidin. days 7 18, while
infection progressed, red blood cell count, hemoglobin hematocrit
dramatically decreased. late phase malarial infection, hepcidin
production reduced concomitantly increase messenger rna
expression hepcidin suppressor erythroferrone bone marrow the
spleen. compared wild-type mice, erfe-/- mice failed adequately suppress 
hepcidin expression infection plasmodium berghei k173. importantly,
the sustained production hepcidin allowed erythroferrone ablation was
associated decreased parasitemia, providing evidence transient 
iron restriction could beneficial treatment malaria.

copyright© ferrata storti foundation.

doi: 10.3324/haematol.2016.150227 
pmcid: pmc5210233
pmid: 27658439  [indexed medline]

